Analysis on the changes of serum angiotensin-converting enzyme and C reactive protein in liver cirrhosis patients

doi:10.3969/j.issn.1673-8640.2013.12.003

Abstract

Abstract:

Objective　 To investigate the changes of serum angiotensin-converting enzyme (ACE) and C reactive protein (CRP) in liver cirrhosis patients. Methods　 A total of 275 patients with liver cirrhosis and 241 healthy subjects (control group) were enrolled, and their serum ACE activities and CRP levels were determined. The patients with liver cirrhosis were classified into Class A (96 cases), Class B (118 cases) and Class C (61 cases) groups according to liver function Child-Pugh classification standard. ACE activity>65 U/L and CRP level >10 mg/L were as positive judgment values, and the positive rates between the 2 groups were compared. All the subjects were classified into low CRP (≤10 mg/L) group (306 cases) and high CRP (>10 mg/L) group (210 cases), and the prevalence rates between the 2 groups were compared. The 275 patients with liver cirrhosis were classified into high ACE (≥ 65 U/L) group (158 cases) and low ACE (<65 U/L) group (117 cases), and the CRP levels between the 2 groups were compared. Serum ACE activities and CRP levels were analyzed by linear correlation analysis. Results　 The serum ACE activities and CRP levels were higher in Class A, B and C groups than in the control group (P<0.01), and the serum ACE activities and CRP levels increased gradually in Class A, B and C groups(P<0.01). For serum ACE activity>65 U/L as positive judgment value, the positive rate was 74.5% in the liver cirrhosis group, and the positive rate was 5.4% in the control group. For CRP level >10 mg/L as positive judgment value, the positive rate was 68.7% in the liver cirrhosis group, and the positive rate was 8.7% in the control group. The prevalence rate in the high CRP group was 90.0% (189/210), and was 28.1% (86/306) in the low CRP group. The former prevalence rate was 3.2 times than the latter prevalence rate. When the low CRP group was as the reference group, the risk odds ratio (OR) in the high CRP group was 7.937 [95% confidence interval (CI): 6.132-10.530, P<0.01]. The CRP level in the high ACE group [28.6(14.8-86.3) mg/L] was significantly higher than that in the low ACE group [15.5(4.3-42.7) mg/L](P<0.01). Serum ACE activities and CRP levels were positively correlated (r=0.468, P<0.01). Conclusions　 The occurrence and development of liver cirrhosis associate with the changes of ACE and CRP. Inflammation and high ACE status play important roles in occurrence and development of liver cirrhosis.

Key words: Angiotensin-converting enzyme, C reactive protein, Liver cirrhosis

CLC Number:

Q555

YAN Feng,XU Weizhen,JIE Weixia,REN Zhenhuan.. Analysis on the changes of serum angiotensin-converting enzyme and C reactive protein in liver cirrhosis patients[J]. , 2013, 28(12): 1073-1076.

References

[1] 张晶,宗春华,李定国,等. 肝内肾素-血管紧张素-醛固酮系统与大鼠肝纤维化的关系[J]. 世界华人消化杂志,2002,10(4):397-400.
[2] Rao MS. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren[J]. J Assoc Physicians India,2010,58:102-108.
[3] Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation,2003,107(3):499-511.
[4] 王蓉,谈介凡,张建平. 血管紧张肽(素)转化酶动力学测定方法的探讨及其初步临床应用[J].检验医学,2011,26(1):19-22.
[5] Yoshiji H,Kuriyama S,Noguchi R,et al. Combination of interferon-beta and angiotensin-converting enzyme inhibitor,perindopril,attenuates the murine liver fibrosis development [J].Liver Int,2005,25(1):153- 161.
[6] Bataller R, Sancho-Bru P, Ginès P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin Ⅱ[J]. Gastroenterology, 2003, 125(1):117-125.
[7] Huang ML, Li X, Meng Y, et al. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors[J]. Clin Exp Pharmacol Physiol,2010,37(1): e1-e6.
[8] Lubel JS,Herath CB,Burrell LM,et al. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications[J]. J Gastroenterol Hepatol,2008,23(9):1327-1338.
[9] Herath CB,Warner FJ,Lubel JS,et al. Upregulation of hepatic angiotensin-converting enzyme 2(ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis[J]. J Hepatol,2007,47(3):387-395.
[10] 高国生,朱海超,胡爱荣,等.乙型肝炎病毒对超敏C反应蛋白表达的影响及其临床意义[J].中华微生物学和免疫学杂志,2011,31(10):931-933.
[11] Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin Ⅱ in hepatic stellate cells and is critical in hepatic fibrosis[J]. J Clin Invest,2003,112(9): 1383-1394.

[1]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[2]	GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051.
[3]	WU Sujun, JI Hengtao, PENG Mengle. Clinical values of IL-18,IL-37,NLRP3 and NK/DC ratio in hepatitis B-related liver cirrhosis [J]. Laboratory Medicine, 2022, 37(6): 518-523.
[4]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[5]	BIE Lihan, FANG Meng, FENG Huijuan, LU Zhicheng, GAO Chunfang. Role of sialylated haptoglobin for the auxiliary diagnosis of hepatitis B-related hepatocellular carcinoma [J]. Laboratory Medicine, 2020, 35(11): 1147-1152.
[6]	LI Zhifeng, LIU Dabiao, GUO Lanfang. Serum angiotensin-converting enzyme in the early diagnosis of pregnancy-induced hypertension [J]. Laboratory Medicine, 2018, 33(6): 495-498.
[7]	KANG Haiyan, HAO Ruofei, REN Ciju. Relationship between angiotensin Ⅱ level and the severity of liver cirrhosis [J]. Laboratory Medicine, 2018, 33(12): 1112-1115.
[8]	LIANG Dongyu, HOU Yanqiang, LOU Xiaoli. Relationship of DcR3 expression with Fas expression in patients with chronic hepatitis B,liver cirrhosis and liver cancer [J]. Laboratory Medicine, 2017, 32(3): 178-181.
[9]	ZHANG Xianghui, ZHAO Yuanming, SUN Zhuoxiang, CHENG Panpan, JIN Chao. Correlation study of serum ferritin and high-sensitivity C reactive protein in gestational diabetes mellitus [J]. Laboratory Medicine, 2015, 30(9): 903-905.
[10]	HE Wenjun, HUANG Jiaping, LIANG Weidong, MO Xiang, LIANG Shaohua. Relationships of oxidized low-density lipoproteins and C reactive protein with in-stent restenosis after PCI [J]. Laboratory Medicine, 2015, 30(5): 484-488.
[11]	XU Cheng, XU Yuanhong. The research progress of early warning biomarker for sepsis [J]. Laboratory Medicine, 2015, 30(5): 533-536.
[12]	GU Xiangming, HUANG Jiesheng, LI Yingying, DU Guoyou.. Application of serum homocysteine and C reactive protein in the diagnosis of acute cerebral vascular diseases [J]. Laboratory Medicine, 2015, 30(4): 337-340.
[13]	LI Feng, WEI Qun, HUANG Dongfeng, ZHANG Hon. Expressions and significance of gp96 and Mcl-1 in liver cirrhosis and hepatocellular carcinoma tissues [J]. Laboratory Medicine, 2015, 30(2): 185-190.
[14]	XU Renrong, ZHANG Huihua, ZHU Huali. Investigation on the diagnosis significance of C reactive protein and adenosine deaminase in cerebrospinal fluid among children with meningitis [J]. Laboratory Medicine, 2015, 30(12): 1203-1205.
[15]	ZHU Yuejin, ZHANG Hua, YAO Hongfeng.. Significance of Hcy, MPV, hs-CRP and FIB for the diagnosis of acute cerebral infarction [J]. Laboratory Medicine, 2015, 30(12): 1219-1221.